266 related articles for article (PubMed ID: 1485178)
1. Efficacy of ondansetron tablets in the management of chemotherapy-induced emesis: review of clinical trials.
Beck TM
Semin Oncol; 1992 Dec; 19(6 Suppl 15):20-5. PubMed ID: 1485178
[TBL] [Abstract][Full Text] [Related]
2. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
[TBL] [Abstract][Full Text] [Related]
3. Single-dose ondansetron for the prevention of cisplatin-induced emesis: efficacy results.
Hainsworth JD; Hesketh PJ
Semin Oncol; 1992 Dec; 19(6 Suppl 15):14-9. PubMed ID: 1485176
[TBL] [Abstract][Full Text] [Related]
4. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
[TBL] [Abstract][Full Text] [Related]
5. Ondansetron: prevention of nausea & vomiting in cisplatin based chemotherapy.
Cheirsilpa A; Ratanatharathorn V; Sinlarat P; Chindavijak K; Lousoontornsiri W; Chakrapee-Sirisuk S; Srimuninimit V
J Med Assoc Thai; 1994 Apr; 77(4):201-6. PubMed ID: 7844494
[TBL] [Abstract][Full Text] [Related]
6. Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy.
Arpornwirat W; Albert I; Hansen VL; Levin J; Bandekar RR; Grunberg SM
Cancer; 2009 Dec; 115(24):5807-16. PubMed ID: 19834961
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of oral granisetron versus oral prochlorperazine in preventing nausea and emesis in patients receiving moderately emetogenic chemotherapy.
Burris H; Hesketh P; Cohn J; Moriconi W; Ryan T; Friedman C; Fitts D
Cancer J Sci Am; 1996; 2(2):85-90. PubMed ID: 9166505
[TBL] [Abstract][Full Text] [Related]
8. [Optimal control by ondansetron of acute and prolonged emesis induced by chemotherapy without cisplatin].
Harousseau JL
Bull Cancer; 1996 Jan; 83(1):71-76. PubMed ID: 8672859
[TBL] [Abstract][Full Text] [Related]
9. [Clinical efficacy of GG032X tablets, a new dosage form of ondansetron (fast dispersing tablet), on cisplatin-induced nausea and emesis].
Ariyoshi Y; Nukariya N; Akasaka Y; Suminaga M; Ota J; Ikeda M; Taguchi T
Gan To Kagaku Ryoho; 1997 Jun; 24(8):995-1011. PubMed ID: 9212810
[TBL] [Abstract][Full Text] [Related]
10. A double-blind comparison of the efficacy of two dose regimens of oral granisetron in preventing acute emesis in patients receiving moderately emetogenic chemotherapy.
Ettinger DS; Eisenberg PD; Fitts D; Friedman C; Wilson-Lynch K; Yocom K
Cancer; 1996 Jul; 78(1):144-51. PubMed ID: 8646710
[TBL] [Abstract][Full Text] [Related]
11. [Anti-emetic effect and safety of ondansetron tablet in double-blind comparison with placebo].
Ariyoshi Y; Ota K; Taguchi T; Furue H; Niitani H; Tsukagoshi S; Ikeda M; Akasaka Y; Ohta J; Suminaga M
Gan To Kagaku Ryoho; 1992 Oct; 19(12):2057-70. PubMed ID: 1417014
[TBL] [Abstract][Full Text] [Related]
12. Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy.
Herrstedt J; Apornwirat W; Shaharyar A; Aziz Z; Roila F; Van Belle S; Russo MW; Levin J; Ranganathan S; Guckert M; Grunberg SM
J Clin Oncol; 2009 Nov; 27(32):5363-9. PubMed ID: 19805683
[TBL] [Abstract][Full Text] [Related]
13. [Anti-emetic effect and safety of single dose of ondansetron injection in double-blind comparison study with placebo].
Ohta J; Taguchi T; Furue H; Niitani H; Ota K; Tsukagoshi S; Ariyoshi Y; Ikeda M; Akasaka Y; Suminaga M
Gan To Kagaku Ryoho; 1992 Oct; 19(12):2041-55. PubMed ID: 1417013
[TBL] [Abstract][Full Text] [Related]
14. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
[TBL] [Abstract][Full Text] [Related]
15. [Value of the combination of oral ondansetron with methylprednisolone as soon as the first cure in mild emetogenic chemotherapy. Groupe français d'étude de l'ondansétron].
Coiffier B; Khayat D; Misset JL; Votan B
Bull Cancer; 1997 Aug; 84(8):781-7. PubMed ID: 9339181
[TBL] [Abstract][Full Text] [Related]
16. Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomized clinical trials.
Gralla RJ; de Wit R; Herrstedt J; Carides AD; Ianus J; Guoguang-Ma J; Evans JK; Horgan KJ
Cancer; 2005 Aug; 104(4):864-8. PubMed ID: 15973669
[TBL] [Abstract][Full Text] [Related]
17. A comparison of oral ondansetron syrup or intravenous ondansetron loading dose regimens given in combination with dexamethasone for the prevention of nausea and emesis in pediatric and adolescent patients receiving moderately/highly emetogenic chemotherapy.
White L; Daly SA; McKenna CJ; Zhestkova N; Leal C; Breatnach F; Smelhaus V; Hung IJ; Kowalczyk J; Ninane J; Mitchell T; Haigh C
Pediatr Hematol Oncol; 2000 Sep; 17(6):445-55. PubMed ID: 10989464
[TBL] [Abstract][Full Text] [Related]
18. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869.
Van Belle S; Lichinitser MR; Navari RM; Garin AM; Decramer ML; Riviere A; Thant M; Brestan E; Bui B; Eldridge K; De Smet M; Michiels N; Reinhardt RR; Carides AD; Evans JK; Gertz BJ
Cancer; 2002 Jun; 94(11):3032-41. PubMed ID: 12115394
[TBL] [Abstract][Full Text] [Related]
19. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F;
Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346
[TBL] [Abstract][Full Text] [Related]
20. [Granisetron (per os) compared with ondansetron (per os) in the prevention of nausea and vomiting induced by mildly emetogenic chemotherapies. Groupe de Recherches en Cancerologie du Nord].
Huc P; Block S; Carlier D; Darloy F; Bonneterre ME; Bleuse JP; Fournier C; Bonneterre J
Bull Cancer; 1998 Jun; 85(6):562-8. PubMed ID: 9752283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
